Hoʻouna palekana CAS 1156491-10-9 (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride ʻO ke kumu kūʻai haʻahaʻa loa.
kikoʻī huahana
CAS No. | 1156491-10-9 |
Kumukumu | C9H10ClF2N |
Kaumaha molekula | 205.63200 |
EINECE | 829-852-9 |
Nuipa pololei | 205.046982 |
PSA | 26.02000 |
LogP | 3.28170 |
Nā kūlana mālama | Ka wela lumi, maloʻo |
wehewehe huahana
ʻO Ticagrelor kahi lāʻau antiplatelet waha, ʻo Brilinta kona inoa inoa ʻAmelika, a ʻo Brilique kona inoa inoa Europa. ʻO Ticagrelor kahi mea hoʻokae platelet adenosine diphosphate (ADP) receptor antagonist i hoʻolālā ʻia e pale i nā platelets mai ka hoʻopili pū ʻana a hana i nā clots koko e hiki ai ke alakaʻi i ka puʻuwai a me nā hahau. Ma ʻAmelika Hui Pū ʻIa, ua ʻae mua ʻia ka ticagrelor e ka FDA i Iulai 2011 no ka mālama ʻana i nā poʻe maʻi makua me ka maʻi maʻi coronary (ACS). Hōʻike ka ʻikepili maʻi i ʻoi aku ka maikaʻi o ka ticagrelor ma mua o clopidogrel i ka hōʻemi ʻana i ka make cardiovascular no ka liʻiliʻi o 12 mau mahina ma hope o kahi hanana ACS. Eia kekahi, ua hōʻemi pū ka ticagrelorChemicalbook i ka loaʻa ʻana o ka stent thrombosis (ST) i nā maʻi i loaʻa i nā stents e mālama i ka ACS. I Iune 2020, ua hoʻolaha ʻo AstraZeneca ua ʻae ka US Food and Drug Administration (FDA) i ka anticoagulant Brilinta (ticagrelor) no ka hoʻohana ʻana i nā poʻe maʻi me ka maʻi maʻi coronary artery kiʻekiʻe (CAD) e hōʻemi i ka hopena o ka hōʻeha puʻuwai mua. a i ʻole ka pilikia o ka hahau ʻana. I Nowemapa 2020, ua hoʻolaha ʻo AstraZeneca ua ʻae ka US Food and Drug Administration (FDA) i kahi hōʻailona hou no ka anticoagulant Brilinta (ticagrelor), i hui pū me ka aspirin, no ka mālama ʻana i ka ischemia acute. I nā poʻe maʻi me ka maʻi hemorrhagic a i ʻole transient ischemic attack (TIA), hoʻemi ia i ka hopena o ka hahau ma hope.
wikiō huahana
Ko makou Hale Hana
Hoʻopili
ʻO ka pauka: ʻeke ʻeke alumini alumini pālua pālua no ka laʻana 1kg, a me 25kgs no ka pahu no ka nui
ʻO wai: ka hue i hoʻopaʻa ʻia no ka laʻana 1L, a me 25kgs no ka pahu no ka nui